Intercept Pharmaceuticals Inc. shares (NASDAQ:ICPT) climbed more than 25 percent in heavy midday trading, energized by new top-line data showing that obeticholic acid (OCA), its nonalcoholic steatohepatitis (NASH) therapy, met its primary endpoint in the phase IIb FLINT trial, improving nonalcoholic steatohepatitis (NASH) without worsening fibrosis.